Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)GlobeNewsWire · 5 days ago
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026GlobeNewsWire · 5 days ago
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical OfficerGlobeNewsWire · Sep 30, 2026
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)Defense World · Sep 11, 2026
Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRXDefense World · Sep 1, 2026
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid TumorsGlobeNewsWire · Aug 18, 2026Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.34 | -$0.36 | Miss |
| May 11, 2026 | -$0.36 | -$0.32 | Beat |
| Mar 11, 2026 | -$0.42 | -$0.35 | Beat |
| Nov 6, 2025 | -$0.53 | -$0.43 | Beat |
| Aug 7, 2025 | -$0.62 | -$0.71 | Miss |
| May 8, 2025 | -$0.78 | -$0.92 | Miss |